MedElevator Войти в исследования
← Поиск публикаций

DOI 10.33963/v.phj.105956

Медицинская библиотека · Kardiologia polska · 2025

Effectiveness and safety of direct oral anticoagulants combined with antiplatelet agents in patients with acute coronary syndrome following percutaneous coronary intervention, with or without atrial fibrillation: A systematic review and network meta-analysis.

Cai Yirou, Zhai Changlin, Shen Liang, Xu Shiyong

СтатьяNetwork Meta-AnalysisСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

The use of direct oral anticoagulants (DOACs) in patients with acute coronary syndrome (ACS) is still controversial.

AIMS: To assess the safety and effectiveness of DOACs combined with antiplatelet agents in patients with acute coronary syndrome after percutaneous coronary intervention (PCI).

MATERIAL AND

METHODS

A systematic search was performed across PubMed, Embase, Cochrane Library, and Web of Science, to identify randomized controlled trials focusing on DOACs in ACS patients or those receiving PCI treatment. The search was completed by May 18, 2024. Quality assessment of the included studies was conducted utilizing the risk of bias tool. Subsequently, data analysis was conducted via R software.

RESULTS

In total, 7 articles were included, encompassing 23 301 patients. The DOACs examined included rivaroxaban, dabigatran, and apixaban. The results indicated that in comparison to dual antiplatelet therapy (DAPT) with rivaroxaban, apixaban combined with single antiplatelet therapy (SAPT) reduced stroke risk (odds ratio [OR], 0.48; 95% credible interval [CrI], 0.25-0.91). In comparison to rivaroxaban/SAPT, the risk of stroke was notably elevated with the rivaroxaban/DAPT regimen (OR, 2.27; 95% CrI, 1.01-5.32). Compared to rivaroxaban/DAPT, dabigatran/SAPT had a greater risk of myocardial infarction (MI) (OR, 1.73; 95% CrI, 1.16-2.59). Compared to standard treatment, rivaroxaban/DAPT evidently decreased MI risk (OR, 0.79; 95% CrI, 0.66-0.95). No remarkable differences were found in the risk of bleeding events between the DOACs combined with antiplatelet and standard treatment groups.

CONCLUSION

Our meta-analysis suggests that the dual pathway inhibition antithrombotic regimen does not markedly increase the bleeding risk compared with standard treatments in ACS patients following PCI. Furthermore, compared to traditional antithrombotic regimens, the combination of rivaroxaban with DAPT potentially reduces the risk of MI.

Для цитирования: Cai Yirou, Zhai Changlin, Shen Liang, Xu Shiyong. Effectiveness and safety of direct oral anticoagulants combined with antiplatelet agents in patients with acute coronary syndrome following percutaneous coronary intervention, with or without atrial fibrillation: A systematic review and network meta-analysis.. Kardiologia polska. 2025. DOI: 10.33963/v.phj.105956.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.